刘叔文，二级教授，博士生导师，南方医科大学副校长，多器官损伤防治国家重点实验室副主任，国家药品监督管理局药物代谢研究与评价重点实验室主任，教育部炎症与免疫相关疾病医药基础研究创新中心副主任。为国家万人计划科技创新领军人才，国家百千万人才工程“有突出贡献中青年专家”，国家药典委委员，中国药理学会抗炎免疫药理专委会主任委员，广东省药理学会名誉理事长。主要从事抗病毒药物及抗炎免疫药理学研究，主持国家自然科学基金重点项目等课题40余项，获中国和国际发明专利授权70余件，在Lancet等期刊发表论文350余篇，国际引用18000余次，H指数55，连续入选爱思唯尔2022中国高被引学者和全球前2%顶尖科学家榜单。获中国侨联“侨界贡献奖”、教育部霍英东教育教学奖、广东省教学成果一等奖。

研究领域：

1.抗炎免疫药理学；

2.抗病毒药物药理学。

主要研究方向：

1. HIV、流感、登革、冠状病毒感染机制和药物研发；

2. 病毒相关认知障碍的机制和药物研发；

3. 病毒相关炎症免疫机制和药物研发；

4. 免疫性肾病发病机制和药物研发。

五篇代表作：

[1]Liu SW^#, Xiao GF^#, Chen YB, He YX, Niu JK, Escalante CR, Xiong HB, Farmar J, Debnath AK, Tien P, Jiang SB^*. Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, 2004; 363(9413): 938-947.

[2]Yuan HX, Peng Z, Zhang ML, Li HL, Lu KY, Yang C, Li MM, Liu SW*. Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling. Pharmacological Research. 2024; 210: 107525

[3]Tan SY*#, Li WJ#, Yang C#, Zhan QP, Lu KY, Liu J, Jin YM, Bai JS, Wang L, Li JQ, Li ZF, Yu F, Li YY, Duan YX, Lu L, Zhang T, Wei JQ, Li L, Zheng YT, Jiang SB*, Liu SW*. The gp120-derived amyloidogenic peptides form amyloid fibrils to intensify HIV-1 infection. Cellular & Molecular Immunology. 2024; 21(5):479-494.

[4]Yang C#, Pan XY#, Xu XF, Cheng C, Huang Y, Li L, Jiang SB, Xiao GF*, Xu W*, Liu SW*. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. Signal Transduction and Targeted Therapy. 2020; 5(1): 220. 

[5]Lu KY#, He JF#, Hong CJ#, Li HW, Ruan JA, Wang JS, Yuan HX, Rong BH, Yang C*, Song GP*, Liu SW*. Inhibition of influenza A virus infection by novel C-3-substituted oleanolic acid benzyl amide derivatives by targeting PA-PB1 interaction and showing anti-inflammatory effects. Acta Pharmaceutica Sinica B. 2025; 15(8): 4156-4173

近三年十篇代表研究性论文：

[1]Lu KY#, He JF#, Hong CJ#, Li HW, Ruan JA, Wang JS, Yuan HX, Rong BH, Yang C*, Song GP*, Liu SW*. Inhibition of influenza A virus infection by novel C-3-substituted oleanolic acid benzyl amide derivatives by targeting PA-PB1 interaction and showing anti-inflammatory effects. Acta Pharmaceutica Sinica B. 2025; 15(8): 4156-4173

[2]Yang C#, Wang RY#, Cheng C, Yu JQ, Lu KY, Li HB, Wang JS, Hu GD, Yang H,  He JF, Su H, Zhan QP, Tan SY*, Zhang T*, Liu SW*. Amyloid-like fibrils derived from β-sheets of gp120 contribute to the neuronal pathology of HIV-associated neurocognitive disorders. Acta Pharmaceutica Sinica B. 2025; 15(4): 2273-2277.

[3]Yang C#, Lu KY#, Wang JS#, Su H, Cheng LP, Nong CM, Li HB, Pan XY, Chen YH, Wu Y, Fan XX, Ma QH*, Hu GD*, Liu SW*. Dihydrotanshinone I act as a pan-SARS-CoV-2 therapeutic agent by targeting the N-terminal domain to inhibit viral entry and spike-induced inflammation. Phytomedicine. 2025; 145: 156989.

[4]Yuan HX, Peng Z, Zhang ML, Li HL, Lu KY, Yang C, Li MM, Liu SW*. Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling. Pharmacological Research. 2024; 210: 107525

[5]Tan SY*#, Li WJ#, Yang C#, Zhan QP, Lu KY, Liu J, Jin YM, Bai JS, Wang L, Li JQ, Li ZF, Yu F, Li YY, Duan YX, Lu L, Zhang T, Wei JQ, Li L, Zheng YT, Jiang SB*, Liu SW*. The gp120-derived amyloidogenic peptides form amyloid fibrils to intensify HIV-1 infection. Cellular & Molecular Immunology. 2024; 21(5):479-494.

[6]Jiang P#, Li SS#, Xu XF, Yang C, Cheng C, Wang JS, Zhou PZ*, Liu SW*. TRPV4 channel involvement in HSV-2 infection through increasing Ca²⁺ oscillations. Acta Pharmacologica Sinica. 2023; 44(4): 811-821.

[7]Yang JJ, Pan Y, Zeng XS, Liu SW*, Chen ZP*, Cheng K*. Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation. Acta Pharmaceutica Sinica B. 2023; 13(9): 3782-3801. 

[8]Chen BB#, Wang W#, Liu T, Cao H, Pan W, Xiao Y, Liu SW*, Chen JJ*. Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment. Signal Transduction and Targeted Therapy. 2023; 8: 91. 

[9]Liao YX#, Ye YL#, Liu MJ#, Liu ZH, Wang JS, Li BX, Huo LJ, Zhuang YL, Chen LY, Chen JX, Gao YF, Ning XY, Li SM*, Liu SW*, Song GP*. Identification of N- and C-3 Modified Laudanosoline Derivatives as Novel Influenza PAN Endonuclease Inhibitors with Strong Antiviral Activity. Journal of Medicinal Chemistry. 2023; 66(1): 188-219. 

[10]Cen XH, Wang BQ, Liang YQ, Chen YL, Xiao Y, Du SH, Nandakumar KS, Yin H*, Liu SW*, Cheng K*. Small molecule SMU-CX24 targeting Toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy. Acta Pharmaceutica Sinica B. 2022; 12(9): 3667-3681.